Back

Lipid assessment and achievement of secondary prevention european society of cardiology guideline targets in patients with atherosclerotic cardiovascular disease with and without depression

28 August 2023 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Secondary prevention Secondary Prevention ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Richard Summers

Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Real world prognostic impact and predictors of adherence to statin therapy after STEMI on first year follow up: results from the FAST STEMI registry
Doctor L. Carmagnola (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Long-term aspirin adherence and risk of cardiovascular events and death after myocardial infarction: A nationwide cohort study
Doctor A. Kristensen (Frederiksberg, DK)
Abstract Slides Video
Presentation thumbnail
A global perspective on cardiovascular risk factor management in patients with CHD and different educational level: SURF CHD II
Ms A. Marza Florensa (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Lower income is associated with non-persistence to statin treatment after a first myocardial infarction
Mr K. Ma (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
The effect of implementing a guideline-based approach to achieve target LDL-C levels in very high risk patients. The PENELOPE study one year follow-up results.
Mr S. Van Der Brug (Breda, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention

The Event

Event poster

ESC Congress 2023

28 August 2023 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Suboptimal Lipid Measurement and Statin Use after Percutaneous Coronary Intervention is associated with Increased Mortality: Results of a Real World Registry of 76,264 Patients in NW London
thumbnail
Congress Presentation
The difference between guideline based lipid optimisation and real-world practice in a very high risk population
thumbnail
Congress Session
Changing face of lipid-lowering therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources